<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN" "http://jats.nlm.nih.gov/publishing/1.2/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.2" xml:lang="ru" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="issn">2687-0940</journal-id><journal-title-group><journal-title>Актуальные проблемы медицины</journal-title></journal-title-group><issn pub-type="epub">2687-0940</issn></journal-meta><article-meta><article-id pub-id-type="doi">10.52575/2687-0940-2023-46-2-123-143</article-id><article-id pub-id-type="publisher-id">150</article-id><article-categories><subj-group subj-group-type="heading"><subject>ВНУТРЕННИЕ БОЛЕЗНИ</subject></subj-group></article-categories><title-group><article-title>&lt;strong&gt;Ожирение и ассоциированные с ним заболевания &amp;ndash; проблемные вопросы патогенеза и современные стратегии диагностики и лечения&lt;/strong&gt;</article-title><trans-title-group xml:lang="en"><trans-title>&lt;strong&gt;Obesity and Associated Diseases &amp;ndash; Problematic Issues of&amp;nbsp;Pathogenesis and Modern Strategies for Diagnosis and Treatment&lt;/strong&gt;</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Голивец</surname><given-names>Татьяна Павловна</given-names></name><name xml:lang="en"><surname>Golivets</surname><given-names>Tatyana P.</given-names></name></name-alternatives><email>golivets@ya.ru</email></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Дубоносова</surname><given-names>Диана Геннадьевна</given-names></name><name xml:lang="en"><surname>Dubonosova</surname><given-names>Diana G.</given-names></name></name-alternatives><email>ya.diana-art@yandex.ru</email></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Ликризон</surname><given-names>Сергей Вячеславович</given-names></name><name xml:lang="en"><surname>Likrizon</surname><given-names>Sergey V.</given-names></name></name-alternatives><email>likrizonendo@mail.ru</email></contrib></contrib-group><pub-date pub-type="epub"><year>2023</year></pub-date><volume>46</volume><issue>2</issue><fpage>0</fpage><lpage>0</lpage><self-uri content-type="pdf" xlink:href="/media/journal-medicine/2023/2/123-143.pdf" /><abstract xml:lang="ru"><p>Изучение механизмов патологического влияния ожирения на развитие, течение и исходы ряда социально значимых заболеваний, поиск эффективных мер их лечения и профилактики находятся в ряду приоритетных задач современной медицинской науки и здравоохранения. Накопленная по этой проблеме информация последних десятилетий демонстрирует необходимость новой стратегии для клинической практики, внедрения междисциплинарных подходов к диагностике ожирения и ассоциированной с ним патологии с включением детального метаболического фенотипирования лиц, страдающих ожирением, и персонализированного подхода к лечению. Перед специалистами практического здравоохранения остро стоит задача своевременного определения у пациентов с ожирением степени сердечно-сосудистого риска, ранней диагностики нарушений углеводного обмена, выбора методов безопасной терапии ожирения и разработки эффективных мероприятий профилактики его хронических осложнений. В данном обзоре проанализированы литературные материалы о патогенезе развития ожирения и ассоциированных с ним заболеваний и сформулированы современные стратегические подходы к диагностике, лечению и профилактике данной патологии.</p></abstract><trans-abstract xml:lang="en"><p>The study of the mechanisms of the pathological influence of obesity on the development, course and outcomes of a number of socially significant diseases, the search for effective ways for their treatment and prevention, remain among the priorities for modern medical science and healthcare. The information accumulated on this problem over the past decades demonstrates the need for a new strategy for clinical practice, with the introduction of interdisciplinary approaches to the diagnosis of obesity and associated pathology with the inclusion of detailed metabolic phenotyping of obese individuals and a personalized approach to treatment. The task of timely determination of the degree of cardiovascular risk in obese patients, early diagnosis of carbohydrate metabolism disorders, selection of methods for safe treatment of obesity and the development of effective measures for the prevention of its chronic complications is acute for practical healthcare specialists. This review analyzes the literature materials on the pathogenesis of obesity and associated diseases and formulates modern strategic approaches to the diagnosis, treatment and prevention of this pathology.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>ожирение</kwd><kwd>ассоциированные заболевания</kwd><kwd>патогенетические механизмы</kwd><kwd>лептинорезистентность</kwd><kwd>медикаментозная терапия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>obesity</kwd><kwd>associated diseases</kwd><kwd>pathogenetic mechanisms</kwd><kwd>leptin resistance</kwd><kwd>drug therapy</kwd></kwd-group></article-meta></front><back><ref-list><title>Список литературы</title><ref id="B1"><mixed-citation>Аметов А.С. 2019. Ожирение. Современный взгляд на патогенез и терапию. Том 1. Москва. Изд. Гоэтар-Медиа. 384 с.</mixed-citation></ref><ref id="B2"><mixed-citation>Ахмедов В.А., Голоктионова А.А., Исаева А.С. 2019. Ожирение и микробиота кишечника. Лечащий врач. 7: 68&amp;ndash;71.</mixed-citation></ref><ref id="B3"><mixed-citation>Берштейн Л.М., Коваленко И.Г. 2010. &amp;laquo;Метаболически здоровые&amp;raquo; лица с ожирением и метаболические признаки ожирения у лиц с нормальной массой тела: что за этим стоит? Проблемы эндокринологии. 3: 47&amp;ndash;51.</mixed-citation></ref><ref id="B4"><mixed-citation>Бирюкова Е.В., Платонова Н.М. 2019. Ожирение: состояние проблемы и возможности терапии в&amp;nbsp;XXI&amp;nbsp;веке. Эффективная фармакотерапия. 15&amp;nbsp;(41): 32&amp;ndash;40.</mixed-citation></ref><ref id="B5"><mixed-citation>Бородкина&amp;nbsp;Д.А., Груздева&amp;nbsp;О.В., Квиткова&amp;nbsp;Л.В., Барбараш&amp;nbsp;О.Л. 2017. Распределение жировых отложений: разгадка кажущегося парадокса ожирения в кардиологии? Ожирение и метаболизм. 14&amp;nbsp;(2):3&amp;ndash;8.</mixed-citation></ref><ref id="B6"><mixed-citation>Бутрова С.А., Плохая А.А. Лечение ожирения: современные аспекты. РМЖ. 2001; 24: 1140. https://www.rmj.ru/articles/endokrinologiya/Lechenie_oghireniya_sovremennye_aspekty/</mixed-citation></ref><ref id="B7"><mixed-citation>Груздева О.В., Акбашева О.Е., Дылев Ю.А. 2017. Адипокиновый и цитокиновый профили эпикардиальной и подкожной жировой ткани у пациентов с ишемической болезнью сердца. Бюллетень экспериментальной биологии и медицины. 163&amp;nbsp;(5): 560&amp;ndash;563.</mixed-citation></ref><ref id="B8"><mixed-citation>Дедов И.И., Мокрышева Н.Г., Мельниченко Г.А., Трошина Е.А. 2021. Ожирение. Клинические рекомендации. Consilium Medicum. 2021; 23&amp;nbsp;(4): 311&amp;ndash;325. DOI: 10.26442/20751753.2021.4.200832</mixed-citation></ref><ref id="B9"><mixed-citation>Драпкина О.М., Самородская И.В., Старинская М.А., Ким О.Т., Неймарк А.Е. 2021. Ожирение: оценка и тактика ведения пациентов. Коллективная монография. Москва. ФГБУ &amp;laquo;НМИЦ ТПМ&amp;raquo; Минздрава России; ООО &amp;laquo;Силицея-Полиграф&amp;raquo;. 174 с.</mixed-citation></ref><ref id="B10"><mixed-citation>Древаль А.В. 2018. Диабетологическая практика. Руководство для врачей. Москва. ГЭОТАР-Медиа. 544с. ISBN 978-5-9704-4193-0.</mixed-citation></ref><ref id="B11"><mixed-citation>Куприенко Н.Б., Смирнова Н.Н. 2015. Витамин D, ожирение и риск кадиоренальных нарушений у детей. Артериальная гипертензия. 21 (1): 48&amp;ndash;58.</mixed-citation></ref><ref id="B12"><mixed-citation>Недогода С.В., Вёрткин А.Л., Наумов А.В. 2016. Ожирение и коморбидная патология в практике поликлинического врача (определение, диагностика; немедикаментозное лечение; лечение ожирения и коморбидной патологии). Т. 2. 1 (4): 4&amp;ndash;33.</mixed-citation></ref><ref id="B13"><mixed-citation>Самородская&amp;nbsp;И.В.&amp;nbsp;2014. Индекс массы тела и парадокс ожирения. РМЖ. Кардиология. 2: 170.</mixed-citation></ref><ref id="B14"><mixed-citation>Симаненков В.И., Тихонов С.В., Ильяшевич И.Г. 2017. Эпидемиология, социальные аспекты и патогенез ожирения. Вестник Северо-Западного государственного медицинского университета им. И.И. Мечникова. 21&amp;ndash;27.</mixed-citation></ref><ref id="B15"><mixed-citation>Тимашева Я.Р., Балхиярова Ж.Р., Кочетова О.В. 2021. Современное состояние исследований в области ожирения: генетические аспекты, роль микробиома и предрасположенность к COVID-19. Проблемы эндокринологии. 67 (4): 20&amp;ndash;35. doi: https://doi.org/10.14341/probl12775</mixed-citation></ref><ref id="B16"><mixed-citation>Трошина Е.А., Ершова Е.В. 2018. Фармакотерапия ожирения: что нового? Проблемы эндокринологии. 64&amp;nbsp;(4): 270&amp;ndash;276. https://doi.org/10.14341/probl9315</mixed-citation></ref><ref id="B17"><mixed-citation>Филатова Г.А., Дэпюи Т.И., Гришина Т.И. 2018. Ожирение: спорные вопросы, определяющие метаболическое здоровье. Эндокринология: новости, мнения, обучение. 7 (1): 58&amp;ndash;67.</mixed-citation></ref><ref id="B18"><mixed-citation>Чумакова Г.А. 2016. Методы оценки висцерального ожирения в клинической практике. Российский кардиологический журнал. 4: 89&amp;ndash;96.</mixed-citation></ref><ref id="B19"><mixed-citation>Шварц В.Я. 2013. Воспаление жировой ткани: враг или друг? Цитокины и воспаление. 12 (1&amp;ndash;2):13&amp;ndash;21.</mixed-citation></ref><ref id="B20"><mixed-citation>Шляхто Е.В., Недогода С.В., Конради А.О., Баранова Е.И. 2016. Концепция новых национальных клинических рекомендаций по ожирению. Российский кардиологический журнал. 4&amp;nbsp;(132): 7&amp;ndash;13. http://dx.doi.org/10.15829/1560-4071-2016-4-7-13.</mixed-citation></ref><ref id="B21"><mixed-citation>Abarca-G&amp;oacute;mez L., Abdeen Z.A., Hamid Z.A. 2017. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128&amp;middot;9 million children, adolescents, and adults. The Lancet. 390 (10113): 2627&amp;ndash;2642. doi: 10.1016/s0140-6736(17)32129-3.</mixed-citation></ref><ref id="B22"><mixed-citation>Al‐Daghri N.M. 2013. Visceral adiposity index is highly associated with adiponectin values and glycaemic disturbances. European journal of clinical investigation. 43 (2): 183&amp;ndash;189.</mixed-citation></ref><ref id="B23"><mixed-citation>Appleton S.L., Seaborn C.J., Visvanathan R., Hill C.L. 2013. Diabetes and cardiovascular disease outcomes in the metabolically healthy obese phenotype: a cohort study. Diabetes Care. 36: 2388&amp;ndash;2394.</mixed-citation></ref><ref id="B24"><mixed-citation>Baker A.R., Silva N.F., Quinn D.W. 2006. Human epicardial adipose tissue expresses a pathogenic profile of adipocytokines in patients with cardiovascular disease. Cardiovasc. Diabetol. 13 (5): 1&amp;ndash;16.</mixed-citation></ref><ref id="B25"><mixed-citation>Castro H., Pomar C.A., Pic&amp;oacute; C. 2015. Cafeteria diet overfeeding in young male rats impairs the adaptive response to fed/fasted conditions and increases adiposity independent of body weight. Int. J. Obes. (Lond). 39 (3): 430&amp;ndash;437.</mixed-citation></ref><ref id="B26"><mixed-citation>Fain J.N. 2003. Resistin release by human adipose tissue explants in primary culture. Biochem. Biophys. Res. Commun. 300: 674&amp;ndash;678.</mixed-citation></ref><ref id="B27"><mixed-citation>Fitzgibbons Timothy P., Czech Michael P. 2014. Epicardial and Perivascular Adipose Tissues and Their Influence on Cardiovascular Disease: Basic Mechanisms and Clinical Associations. J. Am. Heart Assoc. 3:e000582.</mixed-citation></ref><ref id="B28"><mixed-citation>Fretts A.M., Howard B.V., Siscovick D.S. 2016. Processed Meat, but Not unprocessed Red Meat, Is Inversely Associated with Leukocyte Telomere Length in the Strong Heart Family Study. J. Nutr. J. Obes. 12: 63&amp;ndash;71.</mixed-citation></ref><ref id="B29"><mixed-citation>Garvey W. Garber Alan J., Mechanick Jeffrey I., Bray George A., Dagogo-Jack Samuel, Einhorn Daniel, Grunberger George, Handelsman Yehuda, Hennekens Charles H., Hurley Daniel L., McGill Janet, Palumbo Pasquale, Umpierrez Guillermo. 2014. The Aace Obesity Scientific Committee. American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the 2014 Advanced Framework for a New Diagnosis of Obesity as a Chronic Disease. Endocrine Practice. 20 (9): 977&amp;ndash;89. doi: 10.4158/EP14280.PS</mixed-citation></ref><ref id="B30"><mixed-citation>Garvey W.T., Mechanick J.I., Brett E.M. 2016. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocr Pract. 22 (Supplement 3): 1&amp;ndash;203. doi: 10.4158/ep161365.gl.</mixed-citation></ref><ref id="B31"><mixed-citation>Global Health Observatory Data Repository. 2013. Report WHO. Geneva: World Health Organization. [cited 2015 Feb 12]. Available from: http://www.euro.who.int/en/health-topics/diseaseprevention/nutrition/country-work/russian-federation2/.</mixed-citation></ref><ref id="B32"><mixed-citation>Gonzalez-Carter D., Goode A.E., Fiammengo R. 2016. Inhibition of leptin-ObR interaction does not prevent leptin translocation across a human blood-brain Barrier model. Journal of Neuroendocrinology. 28 (6). doi: 10.1111/jne.12392</mixed-citation></ref><ref id="B33"><mixed-citation>Coppari R., Bjorbaek C. 2012. Leptin revisited: its mechanism of action and potential for treating diabetes&amp;nbsp;// Nat. Rev. Drug. Discov. 11 (9): 692&amp;ndash;708.</mixed-citation></ref><ref id="B34"><mixed-citation>Dedov I.I., Melnichenko G.A., Romantsova T.I. 2016. The strategy of obesity management: the results of All-Russian observational program &amp;laquo;Primavera&amp;raquo;.&amp;nbsp;Obesity and metabolism. 13 (1): 36&amp;ndash;44. https://doi.org/10.14341/omet2016136-44</mixed-citation></ref><ref id="B35"><mixed-citation>Durrer Schutz D., Busetto L., Dicker D. 2019. European practical and patient-centred guidelines for adult obesity management in primary care. Obes. Facts. Vol. 12 (1): 40&amp;ndash;66.</mixed-citation></ref><ref id="B36"><mixed-citation>Guo F., Garvey W.T. 2015. Development of a Weighted Cardiometabolic Disease Staging (CMDS) System for the Prediction of Future Diabetes. The Journal of Clinical Endocrinology &amp;amp; Metabolism. 100 (10): 3871&amp;ndash;7.</mixed-citation></ref><ref id="B37"><mixed-citation>Guzzardi M.A. 2016. Maternal adiposity and infancy growth predict later telomere length: a longitudinal cohort study. J. Obes. 40 (7): 1063&amp;ndash;1069.</mixed-citation></ref><ref id="B38"><mixed-citation>Hans Hauner. 2005. Secretory factors from human adipose tissue and their functional role. Nutrition Society. 64: 163.</mixed-citation></ref><ref id="B39"><mixed-citation>Iacobellis G., Barbaro G. 2008. The double role of epicardial adipose tissue as pro- and anti-inflammatory organ /Hormone and Metabolic Research. 40 (7): 442&amp;ndash;445.</mixed-citation></ref><ref id="B40"><mixed-citation>Kramer C.K., Zinman B., Retnakaran R. 2013. Are metabolically healthy overweight and obesity benign conditions? A systematic review and meta-analysis. Annals of internal medicine. 159 (11): 758&amp;ndash;769.</mixed-citation></ref><ref id="B41"><mixed-citation>Ladabaum&amp;nbsp;U., Mannalithara&amp;nbsp;A., Myer&amp;nbsp;P.A., Singh&amp;nbsp;G.&amp;nbsp;2014. Obesity, abdominal obesity, physical activity, and caloric intake in US adults: 1988&amp;ndash;2010. Am. J. Med. 127 (8): 717&amp;ndash;727. e12. doi: 10.1016/j.amjmed.2014.02.026.</mixed-citation></ref><ref id="B42"><mixed-citation>Ling&amp;nbsp;C., R&amp;ouml;nn&amp;nbsp;T.&amp;nbsp;Epigenetics in human obesity and type 2 diabetes. 2019. Cell Metab. 29 (5): 1028&amp;ndash;1044. doi: 10.1016/j.cmet.2019.03.009.</mixed-citation></ref><ref id="B43"><mixed-citation>Mirza M.S. 2011. Obesity, Visceral Fat and NAFLD: Querying the Role of Adipokines in the Progression of Nonalcoholic Fatty Liver Disease ISRN. Gastroenterology. 2011: 592404. doi: 10.5402/2011/592404. Epub 2011 Aug 28</mixed-citation></ref><ref id="B44"><mixed-citation>Obesity and overweight. Report of a WHO. 2015 [cited 2016 Apr 18]. Available from: http://www.who.int/mediacentre/factsheets/fs311/en/.</mixed-citation></ref><ref id="B45"><mixed-citation>Obesity and overweight. Report of a WHO. 2020&amp;nbsp;https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.</mixed-citation></ref><ref id="B46"><mixed-citation>Obesity Prevention and Management. 2019. UMHS. med. umich.edu/1info/FHP/practiceguides/obesity/obesity.pdf.</mixed-citation></ref><ref id="B47"><mixed-citation>Ou H.Y., Wang C.Y., Yang Y.C., 2013. The Association between Nonalcoholic Fatty Pancreas Disease and Diabetes. PLoSONE. 8 (5): e62561 https://doi.org/10.1371/journal.pone.0062561.</mixed-citation></ref><ref id="B48"><mixed-citation>Oussaada S.M., van Galen K.A., Cooiman M.I. 2019. The pathogenesis of obesity. Metabolism. 2019. 92: 26&amp;ndash;36.</mixed-citation></ref><ref id="B49"><mixed-citation>Patel L. 2003. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem. Biophys. Res. Commun. 300: 472&amp;ndash;476.</mixed-citation></ref><ref id="B50"><mixed-citation>Popkin&amp;nbsp;B.M., Du&amp;nbsp;S., Green&amp;nbsp;W.D. 2020. Individuals with obesity and COVID‐19: A global perspective on the epidemiology and biological relationships. Obesity Reviews. 1&amp;ndash;17. DOI: 10.1111/obr.13128.</mixed-citation></ref><ref id="B51"><mixed-citation>Ravinet Trillou C., Delgorge C., Menet C. 2004. CB1 cannabi-noid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int. J. Obes. Relat. Metab. Disord. 28 (4): 640&amp;ndash;648.</mixed-citation></ref><ref id="B52"><mixed-citation>Reilly M.P. 2005. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation. 111: 932&amp;ndash;939.</mixed-citation></ref><ref id="B53"><mixed-citation>Richey J.M., Woolcott O. 2017. Re-visiting the endocannabinoid system and its therapeutic potential in obesity and associated diseases. Curr. Diab. Rep. 17 (10): 99.</mixed-citation></ref><ref id="B54"><mixed-citation>Ritter&amp;nbsp;A., Kreis&amp;nbsp;N.N., Louwen&amp;nbsp;F., Yuan&amp;nbsp;J.&amp;nbsp;2020. Obesity and COVID-19: Molecular Mechanisms Linking Both Pandemics. Int. J. Mol. Sci. 21 (16): 5793. doi:10.3390/ijms21165793.</mixed-citation></ref><ref id="B55"><mixed-citation>Romantseva T.I., Ostrovskaya E.V. 2015. Metabolic healthy obesity: definitions, protective factors, clinical significance. Almanakh klinicheskoy meditsini [Almanac of Clinical Medicine]. (Special Issue 1): 75&amp;ndash;86.</mixed-citation></ref><ref id="B56"><mixed-citation>Romero-Corral A., Somers V.K., Sierra-Johnson J. 2007. Diagnostic performance of body mass index to detect obesity in patients with coronary artery disease. European Heart Journal. 28: 2087&amp;ndash;2093.</mixed-citation></ref><ref id="B57"><mixed-citation>Rossi F., Punzo F., Umano G.R. 2018. Role of cannabinoids in obesity. Int. J. Mol. Sci. 19 (9): 2690. doi: 10.3390/ijms19092690</mixed-citation></ref><ref id="B58"><mixed-citation>Schulze M.B. Metabolic health in normal-weight and obese individuals. Diabetologia. 2019; 62 (4): 558&amp;ndash;66. doi:10.1007/s00125-018-4787-8.</mixed-citation></ref><ref id="B59"><mixed-citation>Senthilingam M. 2021. Covid-19 has made the obesity epidemic worse, but failed to ignite enough action. BMJ. 372: n411. doi:10.1136/ bmj.n411. (Published 04 March 2021)</mixed-citation></ref><ref id="B60"><mixed-citation>Su Jong Yu, Won Kim, Donghee Kim. 2015. Visceral Obesity Predicts Significant Fibrosis in Patients With Nonalcoholic Fatty Liver. Disease Medicine. 94 (48): e2159.</mixed-citation></ref><ref id="B61"><mixed-citation>Sun K., Kusminski C.M., Scherer P.E. 2011. Adipose tissue remodeling and obesity. J. Clin. Invest. 121 (6): 2094&amp;ndash;101.</mixed-citation></ref><ref id="B62"><mixed-citation>Wolf Gunter, Ziyadeh Fuad N. Leptin and Renal Fibrosis. 2006. Obesity and the Kidney. Contrib Nephrol. Basel, Karger. 151: 175&amp;ndash;183.</mixed-citation></ref><ref id="B63"><mixed-citation>Zhi C., Huang J., Wang J. 2019. Connection between gut microbiome and the development of obesity. Eur. J. Clin. Microbiol. Infect. Dis. Jul 31 doi: 10.1007/s10096-019-03623-x.</mixed-citation></ref><ref id="B64"><mixed-citation>Zhu&amp;nbsp;L., She&amp;nbsp;Z.-G., Cheng&amp;nbsp;X. 2020. Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. Cell. Metab. 31: 1068&amp;ndash;77. e3. doi: 10.1016/j.cmet.2020.04.021.</mixed-citation></ref></ref-list></back></article>